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Abstract 
Background 
Transmitted HIV-1 drug-resistance mutations(TDR) are transmitted from treatment-failing or 
treatment-naïve patients. Although prevalence of drug-resistance in treatment-failing patients 
has declined in developed countries, TDR prevalence has not. Mechanisms causing this 
paradox are poorly explored. 
Methods 
We included recently-infected, treatment-naïve patients with genotypic-resistance-tests 
performed ≤1year post-infection and <2013. Potential risk factors for TDR were analyzed 
using logistic regression. Association of TDR prevalences with population viral load(PVL) 
from treatment-patients during 1997-2011 was estimated with Poisson regression for all TDR 
and individually for most frequent resistance-mutations against each drug 
class(M184V/L90M/K103N). 
Results 
We included 2421 recently-infected, treatment-naïve patients and 5399 treatment-failing 
patients. TDR prevalence fluctuated considerably over time. Two opposing developments 
could explain these fluctuations: generally continuous increases in TDR(Odds 
Ratio[OR]=1.13,p=0.010), punctuated by sharp decreases when new drug-classes were 
introduced. Overall, TDR prevalence increased with decreasing PVL(Rate 
Ratio[RR]=0.91/1000Log10-PVL,p=0.033). Additionally, we observed that the transmitted 
high-fitness-cost mutation M184V was positively associated with PVL of treatment-failing 
patients carrying M184V(RR=1.50/100Log10-PVL,p<0.001). Such association was absent 
and negative for K103N(RR-K103N=1.00/100Log10-PVL,p=0.99) and L90M(RR-
L90M=0.75/100Log10-PVL,p=0.022), respectively.  
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Conclusions 
Transmission of antiretroviral drug-resistance is temporarily reduced by the introduction of 
new drug classes and driven by treatment-failing and treatment-naïve patients. These 
findings suggest a continuous need for new drugs, early detection/treatment of HIV-1-
infection. 
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Introduction 
Transmission of HIV-1 infection depends strongly on individual levels of plasma viremia [1]. 
When HIV-1-infected patients receive suboptimal treatment or incomplete adherence to anti-
retroviral therapy (ART), drug-resistant viruses emerge and continue replicating. Therefore, 
the general assumption is that drug-resistant viruses are mainly transmitted from treated 
patients with high levels of HIV viremia due to failed treatment [2]. Modern ART reduces the 
viremia levels and transmissibility of HIV-1 more effectively than earlier ART [3], suggesting 
less emergence [4] and transmission of HIV-1 drug-resistance over time. 
In recent years, the incidence and prevalence of acquired drug-resistance mutations (ADRs) 
in treated patients has indeed declined due to effective ART in various developed countries 
[5,6]. However, prevalence of transmitted drug-resistance mutations (TDR) has often 
remained stable [7-9]. TDR may cause early virological failure when patients start their first-
line therapy [10]. Certain TDR can persist for years in the absence of drug pressure after 
seroconversion [11] and have long-term potential to jeopardize the effectiveness of ART; 
other TDR may disappear rapidly and become undetectable via population sequencing 
[11,12]. Recently, transmission of minority variants harboring drug-resistance has been 
demonstrated [13]. Difficulties in detecting TDR upon ART-initiation might therefore 
compromise the treatment success achieved thus far.  
In the current study we aimed at analysing the risk factors of TDR, and resolving the 
discrepant patterns of TDR and ADR prevalence over time. The unique SHCS dataset, which 
is representative for ≥15 years, allows us to determine the impact of temporarily changing 
factors such as numbers of available drug classes. We adapted population viral load (PVL) 
as a tool to assess the spread of drug-resistance and the transmission potential of the 
treatment-experienced population. We focused specifically on TDR during recent infections to 
avoid potential bias caused by different TDR persistence times. 
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Methods 
Study population  
The SHCS, enrolling patients since 1988, is a prospective, nationwide, clinic-based study 
including a biobank. The SHCS is representative for the HIV epidemiology in Switzerland; it 
includes at least 53% of all HIV cases ever diagnosed in Switzerland, 72% of all patients 
receiving ART, and 69% of the nationwide registered AIDS cases [14]. Additionally, we 
enrolled patients from the Zurich Primary HIV-infection study (ZPHI:www.clinicaltrials.gov; 
ID=NCT00537966) which focuses on identifying and treating patients during early infection 
[15]. Ethical approval from all participating institutions and written informed consent from all 
patients was obtained [14-16]. 
To identify the TDR prevalence, we included recently-infected, treatment-naïve patients 
(definition:see below) with a genotypic resistance test (GRT) performed before 1.1.2013. The 
first GRT from each recently-infected, treatment-naïve individual was considered. All 
sequences before 1996 were grouped as ≤1995 because of small sample sizes. For the 
association analysis, in which we tested whether TDR prevalence is associated with the PVL 
from ART-failing patients, we included ART-failing patients from 1997-2011 due to the 
representative availability of VL testing since 1997. 
GRTs stem from routine-clinical testing performed by four laboratories in Switzerland 
authorized by the Federal Office of Public Health. All laboratories perform population-based 
sequencing of the full protease gene and at least codons 28–225 of the reverse transcriptase 
gene using commer ial assays (Viroseq Vs.1 PE Biosystems;Virsoseq Vs. 2, Abbott AG; 
vircoTYPE HIV-1 Assay, Virco Lab) and in-house methods [17] and participate in the yearly 
quality control evaluation by the Agence Nationale de la Recherche du SIDA (ANRS) since 
2002. All sequences are entered into the SHCS drug-resistance database using 
SmartGene’s Integrated Dababase Network System (SmartGene, Zug, Switzerland, IDNS 
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version 3.6.3) [18]. Additionally, we performed systematically retrospective sequencing for 
blood samples that were stored in the biobank before routine genotyping was introduced 
(over 11000 sequences were retrospectively generated). Subtyping was performed on the 
protease and the reverse transcriptase sequence using REGA 2 
(http://jose.med.kuleuven.be/genotypetool/html/subtypinghiv.html). If this method returned 
inconclusive results, the analysis was repeated with the Star analyzer 
(http://www.vgb.ucl.ac.uk/starn.shtml) [19]. 
TDR were identified using the WHO list for surveillance of transmitted HIV drug-resistance 
[20]. 
Definition of recent infection 
To account for potential reversion of TDR in the absence of drug pressure [11,21-25], we 
restricted our study population to treatment-naïve patients having been diagnosed ≤1 year 
after infection. Specifically, we determined recent infection with one of the following methods: 
 (1) Documented acute HIV-1 infection as previously described [15]. 
 (2) Documented seroconversion (<1 year between the last negative and first positive HIV 
tests). 
 (3) For those lacking the data mentioned above, the ambiguity score [26] was used. It is a 
measure of the viral nucleotide diversity from bulk sequencing which estimates the 
infection duration. Sequences with ≤0.5% ambiguous nucleotides were considered to be 
GRTs from recently-infected patients [26]. However, as diversity may be low in long-term 
HIV-infections, patients with a score ≤0.5% and a CD4 count <200 were excluded to 
reduce false positives. For validation of this method, see Supplementary Material. 
The viral burden of treatment-failing patients 
PVL was used to describe the viral burden of ART-failing patients for the coming year on a 
population level. We summed up the log10 transformed VLs from all ART-failing patients of a 
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given year. For further analyses, where we studied the transmission pattern of a specific 
TDR, the total of log10 transformed VLs from ART-failing patients carrying the corresponding 
mutation was used. Only VLs corresponding to a GRT were included for these analyses 
because genotyping was needed to determine drug-resistance mutations. 
To acquire all potential treatment failures, we defined treatment failure as having a VL ≥400 
copies/mL after 180 days of continuous ART. VL measurement was not fully integrated into 
the clinical routine before 1997, so we included VLs from treatment-failing patients during 
1997-2011. Each person contributed to each year once. If a patient had ≥2 VLs measured 
within the same year, we calculated the mean for that year. 
Statistical methods 
Potential risk factors for acquiring any TDR were analyzed using logistic regression. 
Variables investigated were ethnicity (Caucasian, Black, others), gender (male, female), 
transmission group (men having sex with men [MSM], heterosexual transmission [HSX], 
injecting drug users [IDU], others), HIV-1 subtype (B, non-B), and the calendar year of 
sampling (fitted as a continuous variable). Additionally, since we suspected that less optimal 
regimens resulting from fewer choices of available drugs might have influenced TDR 
transmission, we included the number of available drug classes as an ordered categorical 
variable (the p-value was obtained from the test for trend). In Switzerland, HIV-1 treatment 
occurred in five eras, each separated by the introduction of a new drug class: Mono-class 
therapy with nucleoside analogue reverse transcriptase inhibitors (NRTI) was used before 
1996 (1 drug class:≤1996). After the introduction of unboosted protease inhibitors (PI) in 
1996, patients could obtain dual-class regimens (2 classes:1997-1998). Subsequently, non-
nucleoside analogue reverse transcriptase inhibitors (NNRTI) were introduced in 1998 (3 
classes:1999-2000), followed by boosted PI (PI/r) in 2000 (4 classes:2001-2008), and 
integrase inhibitor (InSTI) in 2008 (5 classes:2009-2012). In the model we included binary 
response indicating detection of any TDR from each patient as an outcome. We analyzed 
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variables independently and included those associated significantly with the outcome into the 
multivariable model (HIV subtype and transmission group). We also chose variables a priori 
regardless of univariable significance due to likely biological impacts (sex, year, and number 
of available drug classes). For TDR to individual drug classes, we included the same co-
variables in the multivariable models for reasons of consistency to avoid obtaining a different 
set of variables for each drug class. We found no collinearity and interactions between any 
included variable. Missing data were list-wise deleted. We calculated odds of TDR detection 
from our fitted multivariable model by retaining all co-variables except for year and number of 
available drug classes at baseline, and transformed the predicted odds to annual 
prevalences.  
In the association analysis we applied Poisson regression to assess the association of TDR 
transmission with treatment-failing patients as potential transmitters. We considered annual 
rates of GRTs detecting TDR from recently-infected, treatment-naïve patients as outcome 
and PVL of all treatment-failing patients from the previous year as explanatory variable. We 
further studied the association for the most prevalent drug-resistance mutation for each major 
drug class in the SHCS: M184V, L90M, and K103N for NRTI, PI, and NNRTI, respectively. In 
this individual-mutation analysis, we fitted the model with the annual prevalence of each of 
these three transmitted mutations as outcome and the PVL of ART-failing patients carrying 
the corresponding mutation from the previous year as explanatory variable. We performed 
sensitivity analyses including PVL from the same year of GRTs performed or from two years 
before (see Supplementary Material).  
We expressed our results with 95% CI and two-sided p-values, with p<0.05 being statistically 
significant. Data analyses were performed with Stata 13.0 SE (StataCorp, Texas, USA). 
Subgroup analysis 
Considering that transmission to some SHCS patients may have occurred abroad and that 
the TDR prevalences of those patients would be less relevant to treatment-experienced 
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patients in Switzerland, we repeated the association analyses with only those patients found 
in Swiss transmission clusters, defined phylogenetically [27]. To summarize, HIV-1 subtype B 
pol sequences from 8271 SHCS patients were pooled with foreign pol sequences from the 
Los Alamos Sequence database (n=36230). Clusters were defined as clades containing ≥10 
sequences and consisting of ≥80% sequences from the SHCS. 
 
Results 
Fraction of positive GRTs in the SHCS 
Figure 1 summarizes the fraction of TDR and ADR from all 20120 GRTs sampled before 
1.1.2013 regardless of the infection duration stratified by treatment status 
(naïve/experienced). Specifically, 10504 GRTs were from 7920 treatment-naïve and 9616 
GRTs from 4816 treatment-experienced individuals.  
ADR reached a peak at 85% in 1998 and dropped continuously since then to a plateau at 
~38% in 2009. This strong decrease of fraction of positive GRTs for ADR (linear regression: -
2.8% /year [-3.4%,-2.2%]; p<0.001) was not followed by a parallel decrease but rather a 
slight increase of fraction of positive GRTs for TDR (0.3% /year [0.2%,0.5%]; p<0.001). To 
further dissect this discrepancy and to avoid possible bias introduced by different persistence 
times of TDRs, we focused on studying treatment-naïve patients with GRTs performed within 
recent infection. 
Study population including recently-infected, treatment-naïve and treatment-failing 
patients 
We identified 2421 (31%) recently-infected patients from 7920 treatment-naïve patients in the 
SHCS with ≥1 GRT performed between June 26, 1992 and Dec.18, 2012. Additionally, we 
included 5399 patients having failed ≥ 1 regimen within years 1997-2011, presenting 18097 
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yearly-unique VL measurements. For detailed patient selection, see Figure 2. For 
representativeness of study population see Supplementary Figure S1. 
 
TDR prevalences over time in recently-infected treatment-naïve patients and 
associated risk factors  
TDR prevalences fluctuated substantially over time with the median (range) as follows: 9.1% 
(2.2%, 15.6%) to any drug; 5.8% (2.2%, 14.3%) to NRTI; 2.5% (0, 4.8%) to PI; 1.4% (0, 
5.1%) to NNRTI (Figure 3, black dots). 
We observed two opposing developments in the multivariable logistic model that could 
explain the complex fluctuations of TDR prevalences (Table 1). On the one hand, overall 
TDR prevalence dropped after introduction of new drug classes. In particular, prevalences of 
TDRs significantly dropped after PI/r and InSTI became available. On the other hand, we 
found a linear increase of TDR prevalences when the number of available drug classes 
remained constant (Figure 3). The combination of these two opposing developments resulted 
in TDR prevalences, which increased in the absence of new drugs but decreased sharply 
upon introduction of new drug classes. TDR prevalences predicted from this model were 
shown in Figure 3 (blue lines).  
Additionally, prevalences of TDR to individual drug classes showed similar but not significant 
patterns as mentioned above (Supplementary Table S1.1-S1.3). 
Association of drug-resistance transmission with the viral burden of treatment-failing 
patients 
We further investigated whether drug-resistance transmission was associated with treatment-
failing patients. We fitted annual prevalences of any TDR (outcome) and PVL of treatment-
failing patients from the previous year (explanatory variable) with a Poisson regression 
model. The rate ratio (RR) was 0.91/1000 PVL (0.83, 0.99; p=0.033), indicating a 9% 
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increase of TDR prevalence for a decrease of PVL of ART-failing patients from the previous 
year by 1000 (Figure 4A,E). PVL itself decreased over time (linear regression: -318/year [-
438,-197]; p<0.001). When we considered patients identified in Swiss transmission clusters, 
we found no discernible evidence for an association between TDR and PVL (RR=0.76/1000 
PVL [0.43,1.34]; p=0.34). 
Taken together, our results suggested no or a negative association between TDR 
prevalences and PVL of ART-failing patients from the previous year. 
Transmission of the class specific drug-resistance mutations M184V, L90M, K103N 
The above analysis pooled all TDRs and potentially neglected the differential behavior of 
individual mutations. We therefore performed individual-mutation analysis for the most 
prevalent drug-resistance mutation for each drug class. 
Transmitted M184V increased 1.5 fold for an increase of PVL from ART-failing patients 
carrying M184V from the previous year by 100 (RR=1.50/100 PVL [1.20,1.86]; p<0.001; 
Figure 4B,F). This association increased to ~6 fold when only TDRs from Swiss transmission 
clusters were considered (RR=5.68/100 PVL [1.21,26.7]; p=0.028). On the contrary, we 
observed a negative association between the transmitted L90M and PVL from ART-failing 
patients carrying L90M from the previous year (RR=0.75/100 PVL [0.58,0.96]; p=0.022; 
Figure 4C,G); the association became stronger when TDRs from Swiss transmission clusters 
were considered (RR=0.07/100 PVL [0.01,0.46]; p=0.006). For K103N no association was 
detected (RR=1.00/100 PVL [0.73,1.37]; p=0.99; Figure 4D,H) and RR became negative 
when including only patients from Swiss transmission clusters but without reaching 
significance (RR=0.02/100 PVL [0.0002,1.55]; p=0.078).  
Sensitivity analyses using PVL from different years, and validating the ambiguity score for 
identifying recent infections showed that our results were robust (Supplementary Table S2, 
S3.1, S3.2). For a summary of sample size and method used in each analysis see 
Supplementary Table 4.
 at Fachbereichsbibliothek on January 21, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
Discussion 
In this study we investigated the paradox between the decrease in ADR prevalence [5,6,28] 
and a nearly stable prevalence of TDR [7,8,29-31]. If TDR indeed primarily originate from 
ART-failing patients with ADR, this discrepancy is counterintuitive. We therefore tested 
whether transmission of drug-resistant viruses was dependent on ART-failing patients in the 
SHCS, which is representative for Switzerland, over a 15-year time period. A large, clearly 
defined recently-infected, treatment-naïve population was used to calculate TDR 
prevalences. 
Our results indicate that drug-resistance transmission is not predominantly driven by 
treatment-failing patients, but rather by a complex mixture of both ART-failing and ART-naïve 
patients. Despite PVL of treatment-failing patients decreased continuously, TDR prevalences 
increased over time. When specific TDRs were studied individually, distinct transmission 
patterns emerged. The prevalence of transmitted M184V correlated positively with PVL from 
ART-failing patients carrying M184V from the previous year. This association became 
stronger for patients included in Swiss transmission clusters. This suggests that the 
treatment-failing population is the major transmission source for M184V. In contrast, no 
positive association was found for L90M or K103N. We detected a negative association 
between prevalences of transmitted L90M and PVL from ART-failing patients carrying L90M 
from the previous year. This implies that major transmission reservoirs for these mutations 
are treatment-naïve rather than treatment-failing patients. 
How can we explain such divergent transmission patterns between specific drug-resistance 
mutations? It is most likely due to the differential fitness costs, which represent the reduced 
ability of a virus harboring a drug-resistance mutation to replicate in the absence of the drug 
to which the mutation confers resistance. Generally, drug-resistant viruses will be replaced 
gradually by fitter viruses when drug pressure is not present, and the rate of the replacement 
depends on the degree of the fitness cost [32]. M184V disappears at a fast rate after 
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transmission [11] without drug pressure due to its high fitness cost [33]. Therefore, M184V 
was rarely found in a drug-naïve population and its transmission depends on treatment-failing 
patients. In contrast, low-fitness-cost mutations L90M and K103N [23,34,35] persist longer in 
the absence of drug pressure [23], and may therefore persist within the ART-naïve 
population, which thus becomes an important source for transmission of these mutations.  
This interpretation is further supported by the fact that occurrence of L90M among recently-
infected, treatment-naïve patients has increased years after the PVL from ART-failing 
patients carrying L90M started to decrease (Figure 4), resulting in the negative association 
from the Poisson regression. A similar but weaker phenomenon was observed for K103N. 
Various combinatorial ART-regimens might contribute to differences between transmission 
patterns of L90M and K103N. Drugs selecting for L90M, mainly saquinavir and nelfinavir, 
have been almost unused in Switzerland for many years, indicating circulation of transmitted 
L90M within the treatment-naïve population. On the other hand, drugs selecting for K103N, 
such as efavirenz and nevirapine, are still in heavy use, implying that transmission of K103N 
is fueled both by treatment-failing and treatment-naïve patients.  
Complemented by results from previous phylogenetic analyses [36-38], our study further 
illustrates that the treatment-naïve population is a major source for ongoing transmission of 
low-fitness-cost mutations. Early diagnosis and treatment of HIV-1-infected individuals is 
warranted to block the otherwise self-fueling mechanism of unrecognized TDR, which persist 
in this population due to low fitness costs. 
In the SHCS TDR prevalences fluctuated considerably over time. We hypothesized that 
introductions of new drugs had an effect on these fluctuations, because new drugs improve 
control of viremia in treated patients. Indeed, after each introduction of a new drug class, a 
drop in TDR prevalences was observed: in 1997 after introduction of PI, 1999 after NNRTI, 
2001 after PI/r, and 2009 after InSTI (Figure 3). Despite the universal and unlimited access to 
ART in Switzerland, TDR prevalences could not be reduced over an 18-year study period 
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(Figure 3A). Possibly, even more TDRs would have occurred without a constant influx of new 
therapy options. This highlights the importance of a drug pipeline that constantly delivers new 
medications. 
There are several limitations to this study. Although our study was limited to a single country, 
we believe that our findings are generalizable to settings with similar HIV epidemics and 
treatment policies (for generalizability see Supplementary Material). In the correlation 
analyses we used measures of treatment-failing patients from the previous year because we 
assumed that treatment-failing patients could transmit drug-resistance approximately within 
one year before salvage treatment is fully active. Sensitivity analyses using PVL from the 
same year or two years before revealed similar results to the original model (Supplementary 
Table S2). Furthermore, the lack of positive associations from individual-mutation analyses of 
L90M/K103N does not causally prove that treatment-naïve individuals are the main source 
for the transmission. Though unlikely due to the well-studied transmission dynamics within 
the SHCS [27], we cannot exclude that patients carrying the transmitted L90M/K103N in our 
study population might all have been infected abroad and thus the ART-failing PVL as 
measured in the SHCS would not be relevant. However, the subgroup analysis including only 
patients from Swiss transmission clusters confirmed the same finding. 
Conclusions 
We demonstrated that transmission of antiretroviral drug-resistance is temporarily reduced by 
the introduction of new drug classes and driven both by treatment-failing and treatment-naïve 
patients. These findings suggest a continuous need for new drugs, early detection and early 
treatment of HIV-1 infection to successfully control the spread of TDR in the long term. 
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No. with resistance / 
Total No. in 
subgroup (%)b,c 
OR (95% CI) 
in univariable 
analysis 
p-
value 
OR (95% CI) 
in multivariable 
analysis 
p-
value 
Age 35 (28, 42)c 1.00 (0.98 - 1.01) 0.62 
Ethnicity  0.33 
  Caucasian 182/1985 (9.2) 1.00 (Ref.)  
  Black 16/222 (7.2) 0.77 (0.45 - 1.31)  
  Othersd 9/148 (6.1) 0.64 (0.32 - 1.28)  
HIV Subtype  <0.01 0.03 
  B 167/1683 (9.9) 1.00 (Ref.)  1.00 (Ref.) 
  Non-B 40/672 (6.0) 0.57 (0.40 - 0.82)  0.65 (0.43 - 0.98) 
Sex  0.07 0.10 
  Male 173/1853 (9.3) 1.00 (Ref.)  1.00 (Ref.) 
  Female 34/502 (6.8) 0.71 (0.48 - 1.03)  0.96 (0.60 - 1.55) 
Transmission Groupe   0.03  0.62 
  MSM 129/1248 (10.3) 1.00 (Ref.)  1.00 (Ref.) 
  HSX 52/770 (6.8) 0.63 (0.45 - 0.88)  0.83 (0.52 - 1.30) 
  IDU 22/263 (8.4) 0.79 (0.49 - 1.27)  0.86 (0.51 - 1.45) 
  Others 4/74 (5.4) 0.50 (0.18 - 1.38)  0.57 (0.20 - 1.60) 
No. of available drug classesf   0.77  0.06g
  1 (NRTI) 10/125 (8.0) 0.97 (0.49 - 1.91)  2.99 (0.99 - 9.02) 
  2 (NRTI,PI) 20/220 (9.1) 1.12 (0.68 - 1.84)  2.85 (1.19 - 6.83) 
  3 (NRTI,PI,NNRTI) 25/235 (10.6) 1.33 (0.84 - 2.11)  2.75 (1.36 - 5.55) 
  4 (NRTI,PI,NNRTI,PI/r) 103/1252 (8.2) 1.00 (Ref.)  1.00 (Ref.) 
  5 (NRTI,PI,NNRTI,PI/r,InSTI) 49/523 (9.4) 1.15 (0.81 - 1.65)  0.61 (0.34 - 1.07)  
Year 2005 (2001, 2008)c 1.02 (0.98 – 1.05) 0.32 1.13 (1.03 – 1.23)h 0.01 
Table 1: Univariable and multivariable analysis for the overall TDR prevalencesa 
a. We used logistic regression to model the odds of being detected as carrying TDR. The dependent 
variable was included as a binary response indicating whether any TDR was detected. All co-variables 
were categorical except for age and year that were continuous variables. In the multivariable model, we 
included significant variables from a univariable model: HIV subtype and transmission group. Variables 
chosen a priori to be included regardless of univariable significance were sex, number of available drug 
classes, and calendar year. Missing data were list-wise deleted, resulting that 66/2421=2.7% of patients 
were deleted due to missing subtype.  
b. Number of patients with any drug resistance from the recently-infected, treatment-naïve patients with a 
clearly defined subtype (n = 2355). 
c. For age and year, median (IQR) was shown 
d. Others includes Asian, Hispanic, others, and unknown 
e. MSM: men having sex with men, HSX: heterosexual, IDU: intravenous drug users, Others: others and 
unknown 
f. NRTI: nucleotide reverse transcriptase inhibitor; PI: protease inhibitor; NNRTI: non-nucleotide reverse 
transcriptase inhibitor; PI/r: boosted protease inhibitor; InSTI: integrase inhibitor 
g. p-value was obtained from the test for trend.  
h. increment is per year 
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Figure legends 
Figure 1: Fraction of positive GRTs detecting any drug-resistance mutation for 
acquired and transmitted drug-resistance in the SHCS 
20120 GRTs were generated in total before 1.11.2013 in the SHCS. 10504 GRTs (blue 
triangles) were performed from 7920 patients when they were treatment-naïve (regardless of 
recent infection), and 9616 GRTs (red dots) from 4816 individuals when they were treatment-
experienced. Fractions of positive GRTs detecting any drug-resistance mutation for both 
populations were shown. The annual numbers of included GRTs from treatment-experienced 
(first row, red) and from treatment-naïve (second row, blue) patients were listed below the 
graph. Linear regression with fraction as dependent variable and year as explanatory variable 
showed that the fraction of positive drug-resistance tests in treatment-experienced patients 
has declined substantially over time (-2.8% per year [-3.4%,-2.2%]; p<0.001), whereas the 
fraction of positive drug-resistance tests in treatment-naïve patients has not (0.3% per year 
[0.2%,0.5%]; p<0.001). 
vertical bars = 95% CI 
Figure 2: Patient selection profile 
Numbers outside of the box indicate exclusions. (A) Selection profile for the recently-infected, 
treatment-naïve population. We selected patients enrolled in the SHCS before 1.1.2013 with 
GRTs performed when they were treatment-naïve (n=7920). From them we identified 
patients having GRTs performed during recent infection (≤1 year of infection) according to 
documented infection dates, seroconversions, or ambiguity score and CD4 count. These 
patients thus constitute our basic study population (n=2421). For further analyses such as for 
the uni- and multivariable analysis in Table 1 and for the association analyses in Figure 4A-
4D, 66 and 252 patients were excluded due to additional criteria set for these analyses. 66 
patients did not have a clearly defined subtype, and 252 patients were not sampled between 
1998-2012 (for details see individual descriptions in Table 1 and Figure 4). (B) Selection 
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profile for the treatment-failing population. We chose PVL as an indicator for the viral burden 
from treatment-failing patients on a population level. PVL was defined as the sum of log10 
transformed VLs from treatment-failing patients. We thus selected available VL 
measurements from SHCS patients when they were treatment-experienced. High VLs (≥ 400 
copies/ml) measured after 180 days of and during a continuous therapy were included from 
these patients. Because VL has been fully integrated into clinical routine since 1997, values 
before 1997 were excluded. We calculated a yearly-unique VL from each patient (if ≥ 1 VL 
was available per patient within the same year, the mean was used) and used these values 
for association analysis in Figure 4E. For further association analyses as in Figure 4F-4H, 
where we studied the transmission pattern of a specific TDR, only VLs corresponding with a 
GRT were included because genotyping was needed to determine drug-resistance 
mutations. From VLs having corresponding GRTs we selected those from patients carrying 
M184V, L90M, or K103N for association analysis in Figure 4F, 4G, or 4H, respectively. 
 
Figure 3: Observed and predicted TDR prevalences 
2421 recently-infected, treatment-naïve patients with their first GRTs were included. For each 
year we calculated the percentage of GRTs detecting TDR (black dots) to (A) any drug, (B) 
NRTI, (C) PI, and (D) NNRTI. Additionally, we predicted TDR prevalence (blue dashed lines) 
by holding all co-variables except for year and number of available drug classes at baseline 
from the multivariable logistic regression model (Table 1) and transforming the odds obtained 
from the model. Co-variables included in the model were HIV-1 subtype and transmission 
group due to univariable significance and sex, number of available drug classes, and 
calendar year that were chosen a priori. Missing data were list-wise deleted. Total numbers 
of GRTs included for each year were listed at the bottom of Figure 3 (for observed data in 
black; for predicted data in blue). The reason for a smaller sample size (n=2355) for the 
predicted prevalences was that 66 patients were excluded from the multivariable model due 
to non-classified HIV-1 subtypes.  
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We found that the large fluctuations of the observed TDR prevalences (black dots) could be 
explained by two opposing developments: (1) a continuous increase with time when no new 
drug classes were introduced, and (2) a sharp decrease when a new drug class was 
introduced (orange vertical lines). This combined effect was described by the predicted TDR 
prevalence (blue dashed lines).  
vertical bars = 95% CI 
 
Figure 4: Association analysis for TDR prevalences with PVL from ART-failing patients 
from the previous year 
Poisson regression was used to test the association between TDR and PVL from ART-failing 
patients from the previous year. 2169 patients with recently-infected, treatment-naïve GRTs 
during years 1998-2012 were included as the outcome to account for annual prevalences of 
(A) any TDR, (B) transmitted M184V, (C) transmitted L90M, and (D) transmitted K103N. 
Included as an explanatory variable was (E) PVL of all ART-failing patients, PVL of ART-
failing patients carrying (F) M184V, (G) L90M, and (H) K103N, respectively, during years 
1997-2011. Total numbers of GRTs performed from recently-infected, treatment-naïve 
patients for each year were listed in the first row of the table at the bottom of Figure 4. Annual 
numbers of yearly-unique VLs for all failing patients, noted as PVL (all failing patients), and 
PVL (failing patients with a specific mutation) were listed in the second to forth row.  
We found that PVL of all treatment-failing patients has decreased over time (E; linear 
regression: -318 per year[-438,-197]; p<0.001). Annual prevalences for any TDR was 
negatively associated with PVL of treatment-failing patients from the previous year (A,E; 
RR=0.91 for every 1000 PVL-all increment [0.83,0.99]; p=0.033). Prevalence of transmitted 
M184V was positively associated with PVL from ART-failing patients carrying M184V from 
the previous year (B,F; RR=1.50 for every 100 PVL increment [1.20,1.86]; p<0.001). On the 
other hand, a negative association and no association was found for L90M (C,G; RR=0.75 for 
 at Fachbereichsbibliothek on January 21, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
per 100 PVL increment [0.58,0.96]; p=0.022) and K103N (D,H; RR=1.00 for per 100 PVL 
increment [0.73,1.37]; p=0.99), respectively. 
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Figure 1 
Year ≤ 95 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
experienced 
n=9616 262 616 663 517 622 620 721 690 798 771 524 532 503 414 468 362 285 248
naïve
n=10504 535 837 744 459 524 449 479 491 610 598 651 692 705 736 721 605 456 212
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Figure 3
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Year ≤ 95 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
observed, n=2421 35 96 121 104 120 129 110 136 131 160 194 193 176 186 185 146 122 77
predicted, n=2355 32 93 118 102 113 122 106 130 127 156 189 187 176 181 183 142 122 76
 at Fachbereichsbibliothek on January 21, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
Figure 4!!
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
TDR, n=2169 -- 104 120 129 110 136 131 160 194 193 176 186 185 146 122 77
PVL(all failing patients), n=18097 1421 1528 1580 1437 1619 1631 1592 1411 1250 1149 986 813 668 570 442 --
PVL (failing patients with M184V), n=2159 292 253 236 179 233 185 195 176 100 94 74 52 38 30 22 --
PVL (failing patients with L90M), n=925 50 107 111 99 110 90 101 84 54 38 40 19 12 5 5 --
PVL (failing patients with K103N), n=680 6 15 33 51 82 77 103 76 49 47 48 28 32 18 15 --
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